Get started
Author

Liting Xue

Observed names: Liting Xue, Kun Wang, Xinxin Li, Janine Y Yang, Wenjie Song, Renhong Tang, WenQing Yang, Xue Liting, Xue, Liting
Observed institutions: University of Massachusetts Chan Medical School, Shanxi Medical University, Capital Medical University, First Affiliated Hospital of Xiamen University, Simcere Pharmaceutical (China), Shanxi Provincial People’s Hospital
ORCID: 0009-0001-4294-1955
Observed ORCIDs: 0009-0001-4294-1955, 0000-0002-5277-4433
OpenAlex ID: A5100616927
A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia
2014 · Leyuan Ma, Yi Shan, et al. · Science Translational Medicine · 136
A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice
2015 · Anuradha Illendula, John A. Pulikkan, et al. · Science · 122
A comparison of transcriptome analysis methods with reference genome
2022 · Xu Liu, Jialu Zhao, et al. · BMC Genomics · 64
PDF
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling
2012 · John Anto Pulikkan, Dmitri Madera, et al. · Blood · 54
PDF
Map4k4 Negatively Regulates Peroxisome Proliferator-activated Receptor (PPAR) γ Protein Translation by Suppressing the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Cultured Adipocytes
2009 · Kalyani V.P. Guntur, Adilson Guilherme, et al. · Journal of Biological Chemistry · 43
PDF
NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis
2014 · Liting Xue, John A. Pulikkan, et al. · Blood · 35
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
2021 · Liting Xue, Xingyuan Gao, et al. · BMC Cancer · 22
PDF
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
2023 · Feng Zhou, Guimei Yang, et al. · Breast Cancer Research · 18
PDF
SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors
2024 · Zhiyong Yu, Yi Kuang, et al. · MedComm · 13
PDF
Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors
2022 · Peng Gu, Liting Xue, et al. · Frontiers in Oncology · 12
PDF
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy
2025 · Wei Zhu, Lei Jiang, et al. · Journal of Medicinal Chemistry · 7
A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents
2022 · Leilei Guo, Xiaokang Qin, et al. · Frontiers in Pharmacology · 7
Abstract LB271: Synergistic anti-tumor efficacy in olaparib-sensitive and -resistant models via simultaneously inhibition of USP1 and PARP
2024 · Shuqun Yang, Zhengtao Li, et al. · Cancer Research · 5
Abstract 5434: Discovery of SCR-7952, a novel, potent and high selective MAT2A inhibitor shows robust anti-tumor activities and better safety profile
2022 · Feng Zhou, Feng Tang, et al. · Cancer Research · 4
Abstract PS15-01: A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+/HER2- locally advanced or metastatic breast cancer
2024 · Jiong Wu, Jian Zhang, et al. · Cancer Research · 3
Abstract 5946: ZM-412, a potent and selective KIF18A inhibitor with robust efficacy as monotherapy in CIN-positive tumors and in combination with MMAE-conjugated ADC in CIN-negative tumors
2024 · Feng Zhou, Lei Zhou, et al. · Cancer Research · 3
Abstract 3474: Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody
2023 · Feng Zhou, Zhengtao Li, et al. · Cancer Research · 3
PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia
2014 · Leyuan Ma, Yi Shan, et al. · Blood · 3
Deletion Of Core Binding Factors Runx1 and Runx2 Leads To Perturbed Hematopoiesis In Multiple Lineages
2013 · John Anto Pulikkan, Xue Liting, et al. · Blood · 3
Technical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology research
2024 · Wenjing Li, Chunlei Xia, et al. · International Immunopharmacology · 2
Abstract 6201: Identification of SP-002, a highly selective USP1 inhibitor effectively inhibits HRD tumor growth and displays low hematotoxicity risk
2023 · Feng Zhou, Zhengtao Li, et al. · Cancer Research · 2
Abstract 5441: Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer
2022 · Peng Gu, Liting Xue, et al. · Cancer Research · 2
Abstract 2157: SCR-6277, a potent and high selective arginine methyltransferase 5 (PRMT5) inhibitor with high tumor/plasma distribution ratio demonstrated robust anti-tumor activities and decreased hematological toxicities
2022 · Feng Zhou, Guimei Yang, et al. · Cancer Research · 2
Abstract 5642: Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers
2022 · Feng Zhou, Guimei Yang, et al. · Cancer Research · 2
Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML
2014 · John Anto Pulikkan, Anuradha Illendula, et al. · Blood · 2
Works count: 73
Citation count: 576
H-index: 10
I10-index: 10
Year
Topic
Type